(Q51055149)

27 March 2018

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. (English)

1 reference

27 March 2018

author name string

Wan-Ju Xu

1

1 reference

27 March 2018

Bao-Li Guo

2

1 reference

27 March 2018

Yu-Gang Han

3

1 reference

27 March 2018

Lei Shi

4

1 reference

27 March 2018

Wan-Shan Ma

5

1 reference

27 March 2018

publication date

12 September 2014

1 reference

27 March 2018

published in

Tumor Biology

1 reference

27 March 2018

volume

35

1 reference

27 March 2018

issue

12

1 reference

27 March 2018

page(s)

12069-12074

1 reference

27 March 2018

Mediterranean diet and hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Letter of retraction. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Diagnosis and treatment of intracranial immature teratoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Towards an integrated proteomic and glycomic approach to finding cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Hepatocellualar carcinoma serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

GP73, a novel Golgi-localized protein upregulated by viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

N-linked glycosylation of the liver cancer biomarker GP73

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

RETRACTED: Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2506-8

Golgi protein 73(GP73), a useful serum marker in liver diseases

21 January 2018

1 reference

12 December 2020

Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma

1 reference

12 December 2020

Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation.

1 reference

12 December 2020

1 reference

12 December 2020

Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

1 reference

12 December 2020

GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review.

1 reference

12 December 2020

International ethical guidelines for biomedical research involving human subjects.

1 reference

12 December 2020

[The guidelines of prevention and treatment for chronic hepatitis B]

1 reference

12 December 2020

Simultaneous electrochemical immunoassay of three liver cancer biomarkers using distinguishable redox probes as signal tags and gold nanoparticles coated carbon nanotubes as signal enhancers

1 reference

12 December 2020

Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.

1 reference

12 December 2020

Serum Golgi Phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma

1 reference

12 December 2020

Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL

1 reference

12 December 2020

Serum Markers of Hepatocellular Carcinoma

1 reference

12 December 2020

A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma

1 reference

12 December 2020

Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma.

1 reference

12 December 2020

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC

1 reference

12 December 2020

10.1007/S13277-014-2506-8

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018